EYPTEyePoint Pharmaceuticals Inc
EYPT
EyePoint Pharmaceuticals Inc8,742
Mkt Cap
$1.08BVolume
783,890.0052W High
$19.1152W Low
$5.57PE Ratio
-3.69EYPT Fundamentals
Price
$12.93Prev Close
$12.78Open
$12.8750D MA
$13.46Beta
1.29Avg. Volume
870,622.22EPS (Annual)
-$3.17P/B
4.68Rev/Employee
$146,593.46$1,055.00
Eyepoint Pharmaceuticals Q1 Earnings Call Highlights
EyePoint Pharmaceuticals (NASDAQ:EYPT) executives told investors the company is approaching what they described as a "pivotal inflection point" for its lead program, DURAVYU, with phase III wet age-related macular degeneration (wet AMD) top-line data expected beginning mid-year and a rapidly enrolli...
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates
EyePoint (EYPT) delivered earnings and revenue surprises of -25.32% and +132.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Analysts
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have...
Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday
Eyepoint Pharmaceuticals (NASDAQ:EYPT) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Sells $36,555.00 in Stock
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction on Friday, April 17th. The shares were sold...
Insider Selling: Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Sells 2,437 Shares of Stock
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed...
JPMorgan Chase & Co. Sells 217,150 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT
JPMorgan Chase & Co. cut its stake in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 87.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,262 shares of the company's stock after selling 217,150 share...
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by Brokerages
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has earned a consensus recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat reports...
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.7% - Time to Sell?
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 3.7% - Time to Sell...
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 101.6% in the 4th quarter, according to its most recent filing with the Securities and...
<
1
2
...
>
Compact View
Not available
Not available